Litcius/Paper detail

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases

Brian S. Gerstenberger, Catherine M. Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, F.F. Vajdos, Lei Xing, Xiaojing Yang, Xin Yang, Stephen W. Wright

2020Journal of Medicinal Chemistry75 citationsDOIOpen Access PDF

Abstract

).

Topics & Concepts

Tyrosine kinase 2ADMEChemistryTyrosine kinaseDrug discoveryKinaseSignal transductionReceptorPharmacologyComputational biologyBiochemistryPlatelet-derived growth factor receptorBiologyIn vitroGrowth factorCytokine Signaling Pathways and InteractionsMast cells and histamineMonoclonal and Polyclonal Antibodies Research
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases | Litcius